• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过分子对接探索CCK1受体上吡啶并嘧啶配体的结合口袋。

Exploring the binding pocket for pyridopyrimidine ligands at the CCK1 receptor by molecular docking.

作者信息

Toumi-Maouche Amel, Maouche Boubekeur, Taïri-Kellou Safia, El-Aoufi Salima, Martín-Martínez Mercedes, González-Muñiz Rosario, Fourmy Daniel, Maigret Bernard

机构信息

Laboratoire de Physico-Chimie Théorique et Chimie Informatique, Faculté de CHIMIE, USTHB B.P. 32, El Alia, Alger, Algeria,

出版信息

J Mol Model. 2008 Apr;14(4):303-14. doi: 10.1007/s00894-008-0271-6. Epub 2008 Feb 20.

DOI:10.1007/s00894-008-0271-6
PMID:18286312
Abstract

Pyridopyrimidine-based analogues are among the most highly potent and selective antagonists of cholecystokinin receptor subtype-1 (CCK1R) described to date. To better understand the structural and chemical features responsible for the recognition mechanism, and to explore the binding pocket of these compounds, we performed automated molecular docking using GOLD2.2 software on some derivatives with structural diversity, and propose a putative binding conformation for each compound. The docking protocol was guided by the key role of the Asn333 residue, as revealed by site directed mutagenesis studies. The results suggest two putative binding modes located in the same pocket. Both are characterized by interaction with the main residues revealed by experiment, Asn333 and Arg336, and differ in the spatial position of the Boc-Trp moiety of these compounds. Hydrophobic contacts with residues Thr117, Phe107, Ile352 and Ile329 are also in agreement with experimental data. Despite the poor correlation obtained between the estimated binding energies and the experimental activity, the proposed models allow us to suggest a plausible explanation of the observed binding data in accordance with chemical characteristics of the compounds, and also to explain the observed diastereoselectivity of this family of antagonists towards CCK1R. The most reasonable selected binding conformations could be the starting point for future studies. Figure Superimposition of the two putative binding conformations revealed by molecular docking for pyridopyrimidine-based CCK1 antagonists.

摘要

基于吡啶嘧啶的类似物是迄今为止所描述的胆囊收缩素受体亚型1(CCK1R)最具效力和选择性的拮抗剂之一。为了更好地理解负责识别机制的结构和化学特征,并探索这些化合物的结合口袋,我们使用GOLD2.2软件对一些具有结构多样性的衍生物进行了自动分子对接,并为每种化合物提出了一个假定的结合构象。定点诱变研究表明,对接方案受Asn333残基的关键作用引导。结果表明在同一口袋中有两种假定的结合模式。两者都以与实验揭示的主要残基Asn333和Arg336相互作用为特征,并且这些化合物的Boc-Trp部分的空间位置不同。与Thr117、Phe107、Ile352和Ile329残基的疏水接触也与实验数据一致。尽管估计的结合能与实验活性之间的相关性较差,但所提出的模型使我们能够根据化合物的化学特征对观察到的结合数据提出合理的解释,并且还能解释该类拮抗剂对CCK1R观察到的非对映选择性。最合理选择的结合构象可能是未来研究的起点。图基于吡啶嘧啶的CCK1拮抗剂分子对接揭示的两种假定结合构象的叠加。

相似文献

1
Exploring the binding pocket for pyridopyrimidine ligands at the CCK1 receptor by molecular docking.通过分子对接探索CCK1受体上吡啶并嘧啶配体的结合口袋。
J Mol Model. 2008 Apr;14(4):303-14. doi: 10.1007/s00894-008-0271-6. Epub 2008 Feb 20.
2
Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor.结合分子建模、定点诱变和构效关系研究来确定吡啶并嘧啶拮抗剂在人CCK1受体上的结合位点。
J Med Chem. 2005 Jul 28;48(15):4842-50. doi: 10.1021/jm0501127.
3
The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.胆囊收缩素具有生物学重要性的C末端与非肽类激动剂SR-146,131在人CCK1受体中共享一个共同的结合位点。Met-121在激活过程中起关键作用的证据。
J Biol Chem. 2002 Mar 1;277(9):7546-55. doi: 10.1074/jbc.M108563200. Epub 2001 Nov 27.
4
Molecular mechanism underlying partial and full agonism mediated by the human cholecystokinin-1 receptor.人胆囊收缩素-1受体介导的部分激动和完全激动作用的分子机制
J Biol Chem. 2005 Mar 18;280(11):10664-74. doi: 10.1074/jbc.M409451200. Epub 2005 Jan 4.
5
Modeled structure of a G-protein-coupled receptor: the cholecystokinin-1 receptor.G蛋白偶联受体的模拟结构:胆囊收缩素-1受体。
J Med Chem. 2005 Jan 13;48(1):180-91. doi: 10.1021/jm049886y.
6
Modeling the binding modes of stilbene analogs to cyclooxygenase-2: a molecular docking study.模拟二苯乙烯类似物与环氧化酶-2 的结合模式:分子对接研究。
J Mol Model. 2010 Dec;16(12):1919-29. doi: 10.1007/s00894-010-0679-7. Epub 2010 Mar 17.
7
Cross-interactions of two p38 mitogen-activated protein (MAP) kinase inhibitors and two cholecystokinin (CCK) receptor antagonists with the CCK1 receptor and p38 MAP kinase.两种p38丝裂原活化蛋白(MAP)激酶抑制剂与两种胆囊收缩素(CCK)受体拮抗剂与CCK1受体和p38 MAP激酶的交叉相互作用。
J Biol Chem. 2005 Jun 3;280(22):21384-93. doi: 10.1074/jbc.M408851200. Epub 2005 Mar 16.
8
Molecular docking/dynamics studies of Aurora A kinase inhibitors.极光激酶A抑制剂的分子对接/动力学研究
J Mol Graph Model. 2008 Jun;26(8):1213-22. doi: 10.1016/j.jmgm.2007.11.003. Epub 2007 Nov 17.
9
Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR).对接和分子动力学研究新型抑制剂对表皮生长因子受体(EGFR)的抑制活性。
Med Chem. 2011 Jan;7(1):24-31. doi: 10.2174/157340611794072698.
10
study combining QSAR, docking and molecular dynamics simulation on 2,4-disubstituted pyridopyrimidine derivatives.关于2,4-二取代吡啶并嘧啶衍生物的定量构效关系(QSAR)、对接和分子动力学模拟相结合的研究。
J Recept Signal Transduct Res. 2019 Apr;39(2):167-174. doi: 10.1080/10799893.2019.1641821. Epub 2019 Jul 29.

本文引用的文献

1
Validated ligand binding sites in CCK receptors. next step: computer-aided design of novel CCK ligands.已验证的胆囊收缩素(CCK)受体中的配体结合位点。下一步:新型CCK配体的计算机辅助设计。
Curr Top Med Chem. 2007;7(12):1243-7. doi: 10.2174/156802607780960528.
2
Strategies for design of non peptide CCK1R agonist/antagonist ligands.非肽类CCK1R激动剂/拮抗剂配体的设计策略。
Curr Top Med Chem. 2007;7(12):1180-94. doi: 10.2174/156802607780960537.
3
Pharmacology of CCKRs and SAR studies of peptidic analog ligands.胆囊收缩素受体的药理学及肽类类似物配体的构效关系研究
Curr Top Med Chem. 2007;7(12):1173-9. doi: 10.2174/156802607780960447.
4
How different are structurally flexible and rigid binding sites? Sequence and structural features discriminating proteins that do and do not undergo conformational change upon ligand binding.结构灵活和刚性的结合位点有何不同?区分在配体结合时发生和不发生构象变化的蛋白质的序列和结构特征。
J Mol Biol. 2007 Jan 5;365(1):257-73. doi: 10.1016/j.jmb.2006.09.062. Epub 2006 Sep 29.
5
Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human cholecystokinin-1 receptor.在明确的膜环境中探究GPCR/配体复合物模型:人胆囊收缩素-1受体
Biophys J. 2006 Feb 15;90(4):1232-40. doi: 10.1529/biophysj.105.070599. Epub 2005 Dec 2.
6
Advances in kinetic protein crystallography.动态蛋白质晶体学的进展。
Curr Opin Struct Biol. 2005 Oct;15(5):538-47. doi: 10.1016/j.sbi.2005.08.002.
7
Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor.结合分子建模、定点诱变和构效关系研究来确定吡啶并嘧啶拮抗剂在人CCK1受体上的结合位点。
J Med Chem. 2005 Jul 28;48(15):4842-50. doi: 10.1021/jm0501127.
8
Computer simulation of protein-ligand interactions: challenges and applications.蛋白质-配体相互作用的计算机模拟:挑战与应用
Methods Mol Biol. 2005;305:451-92. doi: 10.1385/1-59259-912-5:451.
9
Modeled structure of a G-protein-coupled receptor: the cholecystokinin-1 receptor.G蛋白偶联受体的模拟结构:胆囊收缩素-1受体。
J Med Chem. 2005 Jan 13;48(1):180-91. doi: 10.1021/jm049886y.
10
Taking X-ray diffraction to the limit: macromolecular structures from femtosecond X-ray pulses and diffraction microscopy of cells with synchrotron radiation.将X射线衍射推向极限:利用飞秒X射线脉冲解析大分子结构以及同步辐射对细胞进行衍射显微镜成像。
Annu Rev Biophys Biomol Struct. 2004;33:157-76. doi: 10.1146/annurev.biophys.33.110502.140405.